cheaper glp-1 Comparing Ozempic, Wegovy and Other Drugs The race for cheaper GLP-1
Description
2025 May;46(5):422-436
If approved, the drug, called MariTide, could make Amgen the first new entrant into a market thats been dominated by Novo Nordisk, which makes Ozempic and Wegovy, and Eli Lilly, which makes Mounjaro and Zepbound
The only program in this comparison with oral tirzepatide
Furthermore, health systems will be interested in understanding the wider benefits of such therapies, e.g., potential cost offsets and lower healthcare resource utilisation from preventing downstream complications of sarcopenia
Food and Drug Administration approvals, some clinicians worry that losing too much weight too fast can also be harmful for health
